GCV Synergize 2017
Skip Content

9 August 2017

SoftBank Vision Fund helps Roivant raise $1.1bn

Roivant Sciences, which is developing a range of drugs through various subsidiaries, has secured $1.1bn in a round led by the $93bn Vision Fund.

Author: Robert Lavine, News Editor

Vision Fund, the investment fund launched by telecommunications firm SoftBank, led a $1.1bn round for Switzerland-based drug developer Roivant Sciences today that also featured existing investors including pharmaceuticals distributor Dexxon.